Glutamine metabolism in adipocytes: a bona fide epigenetic modulator of inflammation

Simon Lecoutre\textsuperscript{a}, Salwan Maqdas\textsuperscript{a,b,c}, Paul Petrus\textsuperscript{d}, Alison Ludzki\textsuperscript{e}, Morgane Couchet\textsuperscript{a}, Niklas Mejhert\textsuperscript{a}, and MIkael Rydén\textsuperscript{a}

\textsuperscript{a}Department of Medicine (H7), Karolinska University Hospital, Stockholm, Sweden; \textsuperscript{b}CHU Clermont-Ferrand, Service D’endocrinologie, Diabétologie et Maladies Métaboliques, Clermont-Ferrand, France; \textsuperscript{c}Faculté de Médecine, Laboratoire GReD, Université Clermont Auvergne, Clermont-Ferrand, France; \textsuperscript{d}Center for Epigenetics and Metabolism, Department of Biological Chemistry, INSERM U1233, University of California, Irvine, CA, USA

ABSTRACT

A chronic low-grade inflammation of white adipose tissue (WAT) is one of the hallmarks of obesity and is proposed to contribute to insulin resistance and type 2 diabetes. Despite this, the causal mechanisms underlying WAT inflammation remain unclear. Based on metabolomic analyses of human WAT, Petrus et al. showed that the amino acid glutamine was the most markedly reduced polar metabolite in the obese state. Reduced glutamine levels in adipocytes induce an increase of Uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) levels via induction of glycolysis and the hexosamine biosynthetic pathways. This promotes nuclear O-GlcNAcylation, a posttranslational modification that activates the transcription of pro-inflammatory genes. Conversely, glutamine supplementation in vitro and in vivo, reversed these effects. Altogether, dysregulation of intracellular glutamine metabolism in WAT establishes an epigenetic link between adipocytes and inflammation. This commentary discusses these findings and their possibly therapeutic relevance in relation to insulin resistance and type 2 diabetes.

Abstract

A chronic low-grade inflammation of white adipose tissue (WAT) is one of the hallmarks of obesity and is proposed to contribute to insulin resistance and type 2 diabetes. Despite this, the causal mechanisms underlying WAT inflammation remain unclear. Based on metabolomic analyses of human WAT, Petrus et al. showed that the amino acid glutamine was the most markedly reduced polar metabolite in the obese state. Reduced glutamine levels in adipocytes induce an increase of Uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) levels via induction of glycolysis and the hexosamine biosynthetic pathways. This promotes nuclear O-GlcNAcylation, a posttranslational modification that activates the transcription of pro-inflammatory genes. Conversely, glutamine supplementation in vitro and in vivo, reversed these effects. Altogether, dysregulation of intracellular glutamine metabolism in WAT establishes an epigenetic link between adipocytes and inflammation. This commentary discusses these findings and their possibly therapeutic relevance in relation to insulin resistance and type 2 diabetes. (Word count:148)

Introduction

White adipose tissue (WAT) is a highly dynamic organ that can rapidly expand in response to caloric oversupply. When energy intake exceeds energetic requirements, adipocytes take up nutrients from the circulation and store them as triglycerides within a unilocular cytoplasmic lipid droplet. In addition to storing lipids, adipocytes are energy sensors that secrete adipokines as well as metabolites which together impact on multiple physiological processes such as hepatic gluconeogenesis, cell proliferation/tissue growth, blood pressure, angiogenesis, coagulation, chemotaxis, and inflammation (reviewed in [1]). Much research has focused on the chronic low-grade inflammation of WAT associated with obesity and insulin resistance. Thus, in the hypercaloric state adipocytes secrete TNFa, IL-6 and other pro-inflammatory cytokines that are important for healthy WAT remodelling and expansion [2]. Hence, the initial phase of WAT expansion is characterized by a transient phase of inflammation which in turn is considered to be an adaptive response with beneficial effects on tissue dynamics [2,3]. However, a constant caloric oversupply...
and expansion of WAT is associated with a non-resolving immune activation which over time becomes maladaptive. This chronic pro-inflammatory state is capable of resetting homoeostatic set-points thereby prompting the development of insulin resistance, in part via ectopic lipid deposition in liver and muscles [4,5]. Yet, our understanding of the events that initiate WAT inflammation in obesity is limited, and the causal relationship between inflammation and the complications of obesity remains a subject of controversy.

Chromatin remodelling links metabolism to inflammation

It has become increasingly evident in the field of immunology that metabolism and energetic states of immune cells regulate inflammation via epigenetic modifications (reviewed in [6]). Thus, metabolites from multiple pathways can remodel the chromatin via different mechanisms and adapt the transcriptional programs to a specific metabolic state. This interaction is therefore crucial to coordinate cellular function and determine cellular identity. Mechanistically, many metabolites constitute substrates or co-substrates for enzymes that regulate gene expression through DNA methylation and post-translational modifications of histones. For instance, acetyl-CoA, produced mainly through glycolysis, β-oxidation and glutaminolysis, serves as an ‘acetyl’ group donor for protein acetyltransferase, a critical step during protein acetylation [6]. Nicotinamide adenine dinucleotide (NAD+) is an essential cofactor for some histone deacetylases (sirtuins) [7]. Alpha-ketoglutarate (αKGA), a metabolite of the TCA cycle and glutamine metabolism, is a crucial co-factor for DNA and histone demethylation by JMJD histone demethylases and 5-methylcytosine hydroxylases (TETs) [8,9]. Other specific metabolites involved in chromatin remodelling include malonyl-CoA for histone malonylation, lactate for histone lactylation and UDP-GlcNAc for histone GlcNAcylaton [10,11,12].

The connections between cellular metabolism and epigenic modifications lead to altered gene transcription. One example of this occurs in pro-inflammatory M1 macrophages which are metabolically characterized by increased glucose uptake and enhanced aerobic glycolysis (reviewed in [13]). In this setting, pyruvate produced by the glycolytic pathway, can either be funnelled into lactate production or transported into mitochondria where it is converted to acetyl-CoA which then feeds into the TCA cycle. Increased TCA cycle activity leads to the accumulation of metabolites like citrate, itaconate and succinate and an increase in ROS production [14]. Lauterbach and colleagues showed that the production of citrate after TLR4 activation results in increased levels of acetyl-CoA via the activity of ATP citrate lyase which promotes histone acetylation. The later triggers the expression of genes encoding pro-inflammatory cytokines [15]. Moreover, increased intracellular lactate levels can also induce histone modification (lysine lactylation) 16–24 h after exposure to M1-polarizing stimuli [11]. Histone lactylation is not required for the pro-inflammatory gene expression; instead, it is implicated in the upregulation of homoeostatic genes that counteract the inflammatory reaction [11].

A link between glutamine metabolism and chromatin remodelling

Recent studies have shown that the interplay between glycolysis and glutamine metabolism is crucial for the induction of the epigenetic and functional changes in immune cells through fumarate accumulation. The latter is driven by enhanced feeding of glutamine into the TCA cycle through glutaminolysis [16]. Thus, Arts et al. demonstrated that the accumulation of fumarate in β-glucan-treated monocytes was essential for trained immunity [16]. Fumarate accumulation induced epigenetic changes by inhibition of H3K4 demethylase KDM5A, thereby increasing H3K4me3 histone modification (i.e. permissive chromatin) and promoting pro-inflammatory cytokine production upon re-stimulation with LPS [16]. These findings are in line with the role of glutamine metabolism in immune cell differentiation [17,18]. Indeed, glutaminolysis induced by IL4, leads to increased αKGA levels, a substrate for the histone demethylase JMJD3. This enzyme allows demethylation of H3K27 and hence, full activation M2-associated genes [17]. Moreover, in T cells, glutaminase activity suppresses effector T cell differentiation and function [18]. Altogether, this demonstrates that glutamine metabolism plays a key role in the regulation of the inflammatory response of immune cells.

The immunomodulatory potential of glutamine in adipose tissue

In contrast to immune cells, very little is known about the interplay between metabolism and chromatin remodelling in adipocytes. Recently, Petrus et al. reported that altered glutamine metabolism in hypertrophic adipocytes, modulates the expression of pro-inflammatory pathways in white adipocytes [19]. In an untargeted analysis of polar metabolites from human WAT, glutamine was one of the most significantly
altered metabolites in obesity. Analyses in different clinical cohorts revealed that the reduction of glutamine was closely linked to different parameters related to WAT inflammation. A causal relationship was suggested by the observation that intra-peritoneal administration of glutamine in high fat diet-fed mice decreased WAT inflammation and macrophage infiltration. Attenuated WAT glutamine levels in obesity were linked to reduced glutamine synthetase (GLUL) expression in several cell types although the reduction was most prominent in adipocytes [19]. Anti-inflammatory effects of GLUL-mediated glutamine production have been described in several cell types including murine microglia [20], T cells [18,21,22] and macrophages [23,24], as well as adipocytes differentiated from a murine cell line [23].

Given that metabolic pathways are interconnected, and metabolite fluxes change over time, it was hypothesized that dysregulation of glutamine metabolism involved a global metabolic reprogramming of WAT. By combining metabolomics and bioenergetic analyses of human in vitro differentiated adipocytes, Petrus et al. observed that glutamine inhibits glycolysis and the hexosamine biosynthetic pathway resulting in a reduction of UDP-GlcNAc levels. This metabolite is the only substrate for the enzyme O-GlcNAc transferase enzyme (OGT), which catalyzes the post-translational modification of protein targets by adding O-GlcNAc to serine or threonine residues. O-GlcNAcase (OGA) catalyzes the hydrolysis of this sugar modification [25]. Unlike traditional glycosylation, protein O-GlcNAcylation can occur in the cytoplasm, nucleus, and mitochondria and it is an essential post-translational modification allowing dynamic control of protein stability, localization, transcriptional activity and multiple other cellular functions [26]. Numerous studies have shown that transcription factors and cofactors are modified by O-GlcNAcylation [27]. The pathophysiological relevance of this epigenetic modification is supported by several studies reporting that perturbations in cellular O-GlcNAc homoeostasis are linked to a plethora of human diseases, including the pathogenesis of both type-1 and type-2 diabetes [28].

The possible mechanisms through which glutamine and O-GlcNAcylation might regulate gene expression was explored in human in vitro differentiated adipocytes. This demonstrated that glutamine reduced UDP-GlcNAc levels and decreased nuclear protein O-GlcNAcylation in the promoter regions of pro-inflammatory genes. This effect was counteracted by treatment with an OGA inhibitor. A genome-wide de novo motif analysis of the chromatin regions displaying glutamine-linked changes in O-GlcNAcylation revealed an enrichment of the binding motif for SP1, a transcription factor that plays a central role in the regulation of pro-inflammatory responses. It has been shown in other cell systems that O-GlcNAcylation modulates SP1 activity and plays a role in hyperglycemia-induced inflammation [29]. By immunoprecipitation of O-GlcNAc-modified proteins isolated from nuclei of human adipocytes, Petrus et al. confirmed that glutamine reduced both SP1 O-GlcNAcylation and the expression of SP1-regulated target genes. Importantly, SP1 O-GlcNAcylation modified by glutamine is only one example and a wide range of additional O-GlcNAcylated proteins may be regulated by glutamine. Nevertheless, this establishes a link between glutamine, O-GlcNAcylation and inflammatory response and provides the basis for future studies to understand the regulation of nuclear O-GlcNAcylation and its broader role in gene regulation (Figure 1).

The unresolved link between glutamine and glycolysis

The findings above demonstrate that glutamine inhibits glycolysis and thereby the hexosamine pathway. An interaction between glycolysis and glutamine metabolism has been known for long but how these two pathways influence each other remains unclear [30]. Previous studies have suggested that the crosstalk is partially mediated by metabolites such as NAD(P)H, alpha ketoglutarate, succinate and/or citrate (reviewed in [31]). These metabolites can act as cofactors, controlling directly (allosterically) or indirectly (via AMPK, mTORC, HIF1) the activity/expression of specific enzymes involved in glucose and glutamine metabolism (reviewed in [31]). Nevertheless, future studies are required to establish the direct link between glutamine and glycolysis in white adipocytes.

Clinical implications and perspectives

Altogether, these data demonstrate that, similar to immune cells, adipocytes sense changes in the metabolic state resulting in an inflammatory response. Given the strong correlation between WAT glutamine levels (and GLUL expression) and adipocyte volume, it is conceivable that reduced local glutamine levels secondary to adipocyte hypertrophy activate inflammation to promote WAT expansion. This response is dynamic; it is reversed once energy homoeostasis has been achieved but becomes maladaptive in conditions of constant caloric oversupply. The potential clinical implication of glutamine has been studied in a plethora of conditions ranging from critical illnesses [32] to the metabolic syndrome [33] and type 2 diabetes [34]. Short-term glutamine supplementation is
associated with reductions in body weight and fat mass as well as improved insulin sensitivity and glucose homoeostasis [33,35]. Moreover, it results in higher incretin levels promoting insulin secretion in type 2 diabetic patients [36]. Glutamine may therefore constitute an interesting therapeutic compound to reduce WAT inflammation, a cornerstone in type 2 diabetes pathophysiology. In summary, the results by Petrus et al, highlight novel aspects on the molecular mechanisms driving inflammation suggesting that glutamine plays a key role in regulating obesity-associated inflammation in WAT. In this regard, it will be important to identify the transcriptional regulatory network that controls glutamine metabolism in WAT and why it is perturbed in the obese state. Future investigations are needed to understand the dynamics of this immunometabolic crosstalk. Ultimately, these insights might offer new therapeutic perspectives and identify nutritional interventions that target WAT inflammation and insulin resistance.

**Disclosure statement**

No potential conflict of interest was reported by the authors.

**Funding**

This work was supported by the Diabetesfonden; Knut och Alice Wallenberg’s Stiftelse; Novo Nordisk Fonden; Stockholms Läns Landsting; Vetenskapsrådet.
References

[1] Sun K, Tordjman J, Clément K, et al. Fibrosis and adipose tissue dysfunction. Cell Metab. 2013;18(4):470–477.
[2] Wernstedt Asterholm I, Tao C, Morley T, et al. Adipocyte inflammation is essential for healthy adipose tissue expansion and remodeling. Cell Metab. 2014;20:103–118.
[3] Zhu Q, An YA, Kim M, et al. Suppressing adipocyte inflammation promotes insulin resistance in mice. Mol Metab. 2020;39. DOI: 10.1016/j.molmet.2020.101010.
[4] Kotas ME, Medzhitov R. Homeostasis, inflammation, and disease susceptibility. Cell. 2015;160:816–827.
[5] Reilly SM, Saltiel AR. Adapting to obesity with adipose tissue inflammation. Nat Rev Endocrinol. 2017;13:633–643.
[6] Berger SL, Sassone-Corsi P. Metabolic signaling to chromatin. Cold Spring Harb Perspect Biol. 2016;8:a019463.
[7] Imai SI, Armstrong CM, Kaebelerlein M, et al. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature. 2000;403:795–800.
[8] Tahiliani M, Koh KP, Shen Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009;324:930–935.
[9] Tsukada Y, Fang J, Erdjument-Bromage H, et al. Histone demethylation by a family of JmJC domain-containing proteins. Nature. 2006;439(7078):811–816.
[10] Sabari BR, Zhang D, Allis CD, et al. Metabolic regulation of gene expression through histone acylations. Nat Rev Mol Cell Biol. 2017;18(2):90–101.
[11] Zhang D, Tang Z, Huang H, et al. Metabolic regulation of gene expression by histone lactylation. Nature. 2019;574(7779):575–580.
[12] Leturcq M, Lefebvre T, Vercoutter-Edouart A-S, et al. O-GlcNAcylation and chromatin remodeling in mammals: an up-to-date overview. Biochem Soc Trans. 2017;45:323–338.
[13] Ryan DG, O’Neill LAJ. Krebs cycle reborn in macrophage immunometabolism. Annu Rev Immunol. 2020 Apr 26;38:289–313. Annual Reviews Inc.
[14] Russell DG, Huang L, VanderVen BC, et al. Immunometabolism at the interface between macrophages and pathogens. Nat Rev Immunol. 2019;19:291–304.
[15] Lauterbach MA, Hanke JE, Serefidou M, et al. Toll-like receptor signaling rewires macropoxy metabolism and promotes histone acetylation via ATP-citrate lyase. Immunity. 2019;51:997–1011.e7.
[16] Arts RJW, Novakovic B, Ter Horst R, et al. Glutaminolysis and fumarate accumulation integrate immunometabolic and epigenetic programs in trained immunity. Cell Metab. 2016;24:807–819.
[17] Liu P-S, Wang H, Li X, et al. α-ketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming. Nat Immunol. 2017;18:985–994.
[18] Johnson MO, Wolf MM, Madden MZ, et al. Distinct regulation of Th17 and Th1 cell differentiation by glutaminase-dependent metabolism. Cell. 2018;175:1780–1795.e19.
[19] Petrus P, Lecoutre S, Dollet L, et al. Glutamine links obesity to inflammation in human white adipose tissue. Cell Metab. 2020;31:375–390.e11.
[20] Palmieri EM, Menga A, Lebrun A, et al. Blockade of glutamine synthetase enhances inflammatory response in microglial cells. Antioxid Redox Signal. 2017;26:351–363.
[21] Klyysz D, Tai X, Robert PA, et al. Glutamine-dependent α-ketoglutarate production regulates the balance between T helper 1 cell and regulatory T cell generation. Sci Signal. 2015;8:ra97–ra97.
[22] Metzler B, Gfeller P, Guinet E, et al. Restricting glutamine or glutamine-dependent purine and pyrimidine syntheses promotes human T cells with high FOXP3 expression and regulatory properties. J Immunol. 2016;196:3618–3630.
[23] Palmieri EM, Spera I, Menga A, et al. Glutamine synthetase desensitizes differentiated adipocytes to proinflammatory stimuli by raising intracellular glutamine levels. FEBS Lett. 2014;588:4807–4814.
[24] Ren W, Xia Y, Chen S, et al. Glutamine metabolism in macrophages: a novel target for obesity/t2 diabetes. Adv Nutr. 2019;10:321–330.
[25] Yang X, Qian K. Protein O-GlcNAcylation: emerging mechanisms and functions. Nat Rev Mol Cell Biol. 2017 Jul 01;18:452–465. Nature Publishing Group.
[26] Hart GW, Hart GW, Housley MP, et al. Cycling of O-linked beta-N-acetylglucosamine on nucleocyttoplasmic proteins. Nature. 2007;446. DOI: 10.1038/nature05815.
[27] Jackson SP, Tjian R. O-glycosylation of eukaryotic transcription factors: implications for mechanisms of transcriptional regulation. Cell. 1998;55:125–133.
[28] Ramakrishnan P, Clark PM, Mason DE, et al. Activation of the transcriptional function of the NF-κB protein c-Rel by O-GlcNAc glycosylation. Sci Signal. 2013;6. DOI: 10.1126/scisignal.2004097.
[29] Li Y, Xie M, Men L, et al. O-GlcNAcylation in immunity and inflammation: an intricate system (Review). Int J Mol Med. 2019;44:363–374.
[30] Wang L, Li J-J, Gao L-Y, et al. Molecular link between glucose and glutamine consumption in cancer cells mediated by CtBP and SIRT4. Oncogenesis. 2018;7. DOI: 10.1038/s41389-018-0036-8.
[31] Altman BJ, Stine ZE, Dang CV et al. From Krebs to clinic: glutamine metabolism to cancer therapy. Nat Rev Cancer. 2016 Sep 23;16:619–634. Nature Publishing Group.
[32] Cruzat V, Macedo Rogero M, Noel Keane K, et al. Glutamine: metabolism and immune function, supplementation and clinical translation. Nutrients. 2018;10:1564.
[33] Laviano A, Molfino A, Lacaria MT, et al. Glutamine supplementation favors weight loss in nondieting obese female patients. A pilot study. Eur J Clin Nutr. 2014;68:1264–1266.
[34] Mansour A, Hosseini S, Larijani B, et al. Nutrients related to GLP1 secretory responses. Nutrition. 2013;29(6):813–820.
[35] Grau T, Bonet A, Miñambres E, et al. The effect of l-alanyl-l-glutamine dipeptide supplemented total parenteral nutrition on infectious morbidity and insulin sensitivity in critically ill patients*. Crit Care Med. 2011;39:1263–1268.

[36] Greenfield JR, Farooqi IS, Keogh JM, et al. Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects. Am J Clin Nutr. 2009;89:106–113.